Global CRO reach QED operates as a global CRO with offices in the US and India, offering Phase I through IV clinical trials. Sales opportunities exist in cross-border biopharma collaborations, leveraging their international footprint for multinational trials and regulatory support.

Full-service capabilities Their end-to-end trial management from protocol design to recruitment and regulatory approvals suggests upsell potential for biotech firms seeking turnkey trial solutions, reducing vendor coordination complexity and timeline risk.

Early-stage focus With emphasis on Phase I through IV, there is potential to target emerging biotech startups and mid-stage companies preparing for First-in-Human studies or pivotal trials, offering scalable CRO services aligned with rapid development timelines.

Scale consideration Despite a small internal team, QED can position as an agile partner for smaller sponsors or niche indications, offering personalized service levels and flexible staffing models that may be appealing to cost-conscious ventures.

Tech-enabled efficiency Existing tech stack including AWS, Azure, and enterprise tools indicates capability for digital trial management, data integration, and remote monitoring offerings—opportunities to pitch efficiency-focused solutions and cloud-based data services to sponsors.